Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of $43.83M fell 23.6% year over year, ahead of the -47.4% change in trailing-twelve-month operating expenses. Sequentially, it fell 28.5% from the prior quarter. Over 3 fiscal years it compounded at -10.9% a year.

Context

  • Operating expenses amounted to 534086.1% of revenue in FY2025, down 54136.8 pp from a year earlier.
  • Operating expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -23.6% holds above the trailing-twelve-month pace of -47.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$43.83M-28.5% QoQ
Last fiscal yearDec 2025
$192.27M-46.4% YoY
LTMMar 2026
$189.56M-47.4% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.6%——
1 year-46.4%——
3-year CAGR-10.9%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
192.27M USD
Year-over-year change
-46.4%
4-year CAGR
-3.9%

Operating Expenses vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -47.4% is the 9th highest of 10, against a peer median of -11.1%.
  • Operating expenses amounts to 611487.1% of revenue for LYEL, versus a peer median of 1849.0%.
LYEL Competitors
Operating Expenses for LYEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LYELLyell Immunopharma, Inc.LTM Mar 2026$189.56M USD-47.4%-10.9%611487.1%
CABACabaletta Bio, Inc.LTM Mar 2026$179.4M USD+33.6%+47.1%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$172.43M USD+63.7%+67.8%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$162.92M USD+24.9%+67.1%—
AMRNAmarin Corporation plcLTM Mar 2026$150.13M USD-11.1%-27.1%69.9%
EDITEditas Medicine, Inc.LTM Mar 2026$117.37M USD-46.1%-16.4%303.3%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$112.97M USD-32.5%-15.4%—
SLNSilence Therapeutics plcLTM Mar 2026$87.2M USD—+16.9%9463.1%
ACIUAC Immune S.A.LTM Mar 2026CHF 68.45M CHF-14.4%-1.1%1849.0%
GNLXGenelux CorporationLTM Mar 2026$33.48M USD+7.3%+35.5%418487.5%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$28.32M USD-53.7%-17.4%—
Peer median (excluding LYEL) —-11.1%+7.9%1849.0%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.65M84.68M130K61K36K
Cost of Revenue000011.54M
Gross Profit10.65M84.68M130K61K(11.5M)
Gross Margin100.0%100.0%100.0%100.0%-31952.8%
Research & Development138.69M159.19M182.95M171.6M158.68M
Selling, General & Admin89.06M117.31M66.98M52.04M45.14M
Operating Expenses225.43M271.74M247.14M358.82M192.27M
Depreciation & Amortization13.62M18.02M20.25M19.63M11.54M
EBITDA(236.6M)(165.1M)(214.38M)(200.64M)(262.91M)
EBITDA Margin-2221.5%-195.0%-164909.2%-328923.0%-730302.8%
Operating Income(214.78M)(187.06M)(247.01M)(358.76M)(203.77M)
Operating Margin-2016.7%-220.9%-190006.2%-588123.0%-566038.9%
Interest Income1.17M7.05M23.45M24.07M13.08M
Interest Expense00000
Other Income / Expenses(35.44M)3.94M12.38M15.76M(70.67M)
Income Before Tax(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Pre-Tax Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
Income Tax Expense00000
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Net Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
EPS (Basic)(1.03)(0.74)(0.93)(1.31)(16.06)
EPS (Diluted)(1.03)(0.74)(0.93)(1.31)(16.06)
Weighted Avg Shares12.14M12.35M12.55M13.07M17.09M
Weighted Avg Shares (Diluted)12.14M12.35M12.55M13.07M17.09M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.